A Invesco



Chris Liu Senior Portfolio Manager, China A-shares



Andrew Tong Senior Portfolio Manager, China A-shares Quantitative Strategies

China A-shares 2024 outlook

January 2024

What can we expect in 2024?

Entering 2024 we expect to see more policy support for the China A-shares market, a gradual recovery in investor confidence and structural opportunities in certain industries.

We believe the series of policies to boost the economy that were introduced last year will bear fruit in 2024. While the regulations supporting the property sector may not be enough to ensure a long-term growth trend, we believe these actions can help ensure the sector achieves a soft landing thus decreasing the drag on economic growth compared to 2023.

There is a strong likelihood that the consumption downgrade trend will persist for another one to three years until property prices can stabilize. This is being driven by the negative wealth effect, weak wage growth and high youth unemployment. Consumer confidence varies between different income groups. China's middle class are the least confident consumers given that property accounts for a larger proportion of their net wealth.

There are three catalysts that we believe may help to revive low consumer confidence in 2024: the possible distribution of consumption vouchers in March to boost spending during the post CNY lull, stronger wage growth and an improvement in the labor market if we see economic recovery gain momentum, and a potential pick-up in the birthrate in the auspicious Year of the Dragon which may spur household spending.

Although property and consumption dragged down macroeconomic growth in 2023, at the micro level, we still see the global competitiveness of Chinese companies increasing. We believe the upgrading of China's industrial value chain is an unstoppable trend. Whether it is the surge in exports of new energy vehicles or the launch of self-developed mobile phone chips by China's tech giant breaking through Western technology curbs, China's technological innovation and cost advantages are enabling domestic companies to become strong competitors in advanced manufacturing.

We expect China's continuous upgrading in advanced manufacturing-related industries will bring more import substitution and export opportunities to A-share companies. We also anticipate that China' world-leading green industries such as electric vehicles, solar and wind power will bring opportunities for A-share companies to expand overseas and become new growth drivers.

On the geopolitical front, diplomatic relations between China and the West have improved recently, but the 2024 U.S. election is likely to bring some uncertainty. US interest rates have peaked and are expected to trend downward in 2024, which will help encourage fund flows to emerging markets including the A-share market.

Historically we have seen A-share growth sectors generally outperform value sectors as rates start to fall. The depreciation of the US dollar will also provide more room for China's monetary policy to continue to support economic growth in 2024 (via lowering the reserve ratio and interest rates).

We believe the property sector slowdown will last for some time and do not expect strong GDP growth recovery any time soon. However, 2024 is expected to a better year than 2023, promising many structural investment opportunities for investors.

This document is for Professional Clients only in Dubai, Jersey, Guernsey, the Isle of Man, Continental Europe (as defined in the important information at the end) and the UK; for Institutional Investors only in the United States; for Professional/Qualified/Sophisticated Investors in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and the United Arab Emirates; for Sophisticated or Professional Investors in Australia; in New Zealand for wholesale investors (as defined in the Financial Markets Conduct Act); for Professional Investors in Hong Kong; for Qualified Institutional Investors in Japan; in Taiwan for Qualified Institutions/Sophisticated Investors; in Singapore for Institutional/Accredited Investors; for Qualified Institutional Investors and/or certain specific institutional investors in Thailand; for certain specific sovereign wealth funds and/or Qualified Domestic Institutional Investors approved by local regulators only in the People's Republic of China; for certain specific institutional investors in Malaysia upon request; for certain specific institutional investors in Brunei; for Qualified Professional Investors in Korea; for certain specific institutional investors in Indonesia; for qualified buyers in Philippines for informational purposes only; in Canada, this document is restricted to i) accredited investors and ii) permitted clients as defined under National Instrument 45-106 and 31-103 respectively. It is not intended for and should not be distributed to or relied upon by the public or retail investors. Please do not redistribute this document.



January 2024

Where are we seeing structural investment opportunities?

We are optimistic about China's advanced manufacturing and pharmaceutical sectors in 2024.

Advanced manufacturing

The upgrading of the domestic advanced manufacturing industry is being driven by the strong growth potential of new industries and advancement of homegrown technology.

We believe the humanoid robotics sector has a lot of room to grow in the next five to ten years. The initial stage of this development will focus on commercial applications as breakthroughs in AI foundation models will promote the commercialization of robots. In the long term, as the technology matures and labor costs rise due to a shrinking workforce, humanoid robot applications will gradually expand to the consumer market where it has huge growth potential.

The first step would be to greatly reduce production costs with the help of China's midstream and upstream industrial chains. At the same time, the Chinese government has recently announced several policies to support the humanoid robot industry. We are positive on robotics supply chains that have less overlap with industrial robots, such as the humanoid robotic hand supply chain.

Pharmaceuticals and biotech

The domestic pharmaceutical sector has performed poorly in the past three years. In the first two years the sector was affected mainly by volume-based procurement and geopolitics. In 2023, the concern has been around the anti-corruption campaign in public hospitals.

Looking ahead to 2024, the impact of the anti-corruption campaign is gradually dissipating. We expect high-performing pharmaceutical and medical device companies to gain more market share as companies with high selling expenses and low R&D capabilities will be kicked out of the competition and the industry's profit margin is expected to improve as sales expenses reduce.

We foresee the impact of volume-based procurement to reduce in 2024. This will be particularly salient for pharmaceutical companies as most of their drugs have already been included into the drug reimbursement list and the impact of drug price reductions will be lower.

The growth of global biotech funding has slowed over the past one to two years due to the impact of higher interest rates in the US. However, as rates are likely to fall in 2024, we expect this will promote the recovery of global biotech funding growth and will have a positive impact on China's biotech sector.


After nearly three years of adjustment, valuations of China healthcare companies are well below the 10-year average. We believe long-term demand in this sector is a certain outcome, driven by China's aging population, and therefore the risk reward profile of the healthcare industry is currently at an attractive level.

China A shares outlook

Overall, we believe value factors will continue to outperform should Chinese market sentiment rebound, driven by the large historical discount the market is currently at as well as by valuation re-rating trend of Chinese state-owned enterprises. At the same time, an economic rebound may lead to a tactical outperformance for both leverage and growth factors in 2024. At 10.8x P/E, China's large cap valuations are now at their lowest levels since 2018 and are significantly lower than the 10-year median levels. The valuations of mid cap and small cap stocks are also below their respective 10-year median levels. This historical discount is persistent across all major industries, especially among banks, insurers, and real estate firms.



January 2024



Source: WIND, data as of December 31, 2023. Note: Data based on CSI 300 Index.





Figure 2 - Trailing 12 months PE ratio of China mid cap companies (2014 - 2023)

Source: WIND, data as of December 31, 2023. Note: Data based on CSI 500 Index.

Figure 3 - Trailing 12 months PE ratio of China small cap companies (2014 - 2023)



Source: WIND, data as of December 31, 2023. Note: Data based on CSI 1000 Index.




Figure 4 - A-share companies overall YOY earnings growth

January 2024

The weak economic growth trends over the last two years have exerted pressure on corporate earnings growth. As earnings downgrades are now showing signs of bottoming out, we expect valuations to find support in the near term. The probability of a broad-based earnings recovery in 2024 should not be ignored given the strong fiscal and monetary stimulus measures that have been put in place.

If China's economy could regain a more stable growth momentum, we expect earnings revisions or analyst sentiment factors will improve. Despite a declining interest rate environment, more leveraged companies have been weighed down by the poor economic sentiment in 2023. We expect the leverage factor to rebound in tandem with higher lending growth and an improved liquidity backdrop created by the People's Bank of China's looser monetary policy in 2024.



Source: WIND, data as of December 31, 2023.

China A-shares 2024 outlook

January 2024

Investment risks

The value of investments and any income will fluctuate (this may partly be the result of exchange rate fluctuations) and investors may not get back the full amount invested.

When investing in less developed countries, you should be prepared to accept significantly large fluctuations in value.

Investment in certain securities listed in China can involve significant regulatory constraints that may affect liquidity and/or investment performance.

Important Information

This document is for Professional Clients only in Dubai, Jersey, Guernsey, the Isle of Man, Continental Europe (as defined below) and the UK: for Institutional Investors only in the United States: for Professional/Qualified/Sophisticated Investors in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and the United Arab Emirates: for Sophisticated or Professional Investors in Australia: in New Zealand for wholesale investors (as defined in the Financial Markets Conduct Act); for Professional Investors in Hong Kong; for Qualified Institutional Investors in Japan; in Taiwan for Qualified Institutions/ Sophisticated Investors; in Singapore for Institutional/Accredited Investors; for Qualified Institutional Investors and/or certain specific institutional investors in Thailand; for certain specific sovereign wealth funds and/or Qualified Domestic Institutional Investors approved by local regulators only in the People's Republic of China; for certain specific institutional investors in Malaysia upon request; for certain specific institutional investors in Brunei; for Qualified Professional Investors in Korea; for certain specific institutional investors in Indonesia; for qualified buyers in Philippines for informational purposes only; in Canada, this document is restricted to i) accredited investors and ii) permitted clients as defined under National Instrument 45-106 and 31-103 respectively. It is not intended for and should not be distributed to or relied upon by the public or retail investors. Please do not redistribute this document

The publication is marketing material and is not intended as a recommendation to invest in any particular asset class, security, or strategy. Regulatory requirements that require impartiality of investment/ investment strategy recommendations are therefore not applicable nor are any prohibitions to trade before publication. The information provided is for illustrative purposes only, it should not be relied upon as recommendations to buy or sell securities.

By accepting this document, you consent to communicate with us in English, unless you inform us otherwise.

For the distribution of this document, Continental Europe is defined as Austria, Belgium, Denmark, Finland, France, Germany, Greece, Italy, Ireland, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, and Switzerland.

All articles in this publication are written, unless otherwise stated, by Invesco professionals. The opinions expressed are those of the author or Invesco, are based upon current market conditions and are subject to change without notice. This publication does not form part of any prospectus. This publication contains general information only and does not take into account individual objectives, taxation position or financial needs. Nor does this constitute a recommendation of the suitability of any investment strategy for a particular investor.

Neither Invesco Ltd. nor any of its member companies guarantee the return of capital, distribution of income or the performance of any fund or strategy. Past performance is not a guide to future returns.

This publication is not an invitation to subscribe for shares in a fund nor is it to be construed as an offer to buy or sell any financial instruments. As with all investments, there are associated inherent risks. This publication is by way of information only. This document has been prepared only for those persons to whom Invesco has provided it. It should not be relied upon by anyone else and you may only reproduce, circulate and use this document (or any part of it) with the consent of Invesco. Asset management services are provided by Invesco in accordance with appropriate local legislation and regulations.

Certain products mentioned are available via other affiliated entities. Not all products are available in all jurisdictions.



January 2024

This publication is issued:

- in Hong Kong by Invesco Hong Kong Limited 景順投資管理有限公司, 45/F, Jardine House,
 1 Connaught Place, Central, Hong Kong. This document has not been reviewed by the Securities and Futures Commission.
- in Singapore by Invesco Asset Management Singapore Ltd, 9 Raffles Place, #18-01 Republic Plaza, Singapore 048619.
- in Taiwan by Invesco Taiwan Limited, 22F, No.1, Songzhi Road, Taipei 11047, Taiwan (0800-045-066).
 Invesco Taiwan Limited is operated and managed independently.
- in Japan by Invesco Asset Management (Japan) Limited, Roppongi Hills Mori Tower 14F, 6-10-1 Roppongi, Minato-ku, Tokyo 106-6114; Registration Number: The Director- General of Kanto Local Finance Bureau (Kin-sho) 306; Member of the Investment Trusts Association, Japan and the Japan Investment Advisers Association.
- in Australia by Invesco Australia Limited (ABN 48 001 693 232), Level 26, 333 Collins Street, Melbourne, Victoria, 3000, Australia which holds an Australian Financial Services Licence number 239916.

This document has been prepared only for those persons to whom Invesco has provided it. It should not be relied upon by anyone else. Information contained in this document may not have been prepared or tailored for an Australian audience and does not constitute an offer of a financial product in Australia. You may only reproduce, circulate and use this document (or any part of it) with the consent of Invesco.

The information in this document has been prepared without taking into account any investor's investment objectives, financial situation or particular needs. Before acting on the information the investor should consider its appropriateness having regard to their investment objectives, financial situation and needs.

You should note that this information:

- may contain references to dollar amounts which are not Australian dollars;
- may contain financial information which is not prepared in accordance with Australian law or practices;
- may not address risks associated with investment in foreign currency denominated investments; and
- does not address Australian tax issues.
- in New Zealand by Invesco Australia Limited (ABN 48 001693232), Level 26, 333 Collins Street, Melbourne, Victoria, 3000, Australia which holds an Australian Financial Services Licence number 239916.

This document is issued only to wholesale investors (as defined in the Financial Markets Conduct Act) in New Zealand to whom disclosure is not required under Part 3 of the Financial Markets Conduct Act. This document has been prepared only for those persons to whom it has been provided by Invesco.

It should not be relied upon by anyone else and must not be distributed to members of the public in New Zealand. Information contained in this document may not have been prepared or tailored for a New Zealand audience. You may only reproduce, circulate and use this document (or any part of it) with the consent of Invesco. This document does not constitute and should not be construed as an offer of, invitation or proposal to make an offer for, recommendation to apply for, an opinion or guidance on Interests to members of the public in New Zealand. Applications or any requests for information from persons who are members of the public in New Zealand will not be accepted.

- in the United States by Invesco Advisers, Inc., 1331 Spring Street NW, Suite 2500, Atlanta, Georgia 30309, USA.
- in Canada by Invesco Canada Ltd. 120 Bloor Street East, Suite 700, Toronto, Ontario M4W1B7.
- in **Austria** and **Germany** by Invesco Asset Management Deutschland GmbH, An der Welle 5, 60322 Frankfurt am Main, Germany.
- in Belgium, Denmark, Finland, France, Greece, Italy, Ireland, Luxembourg, Netherlands, Norway, Portugal, Spain and Sweden by Invesco Management S.A., President Building, 37A Avenue JF Kennedy, L-1855 Luxembourg, regulated by the Commission de Surveillance du Secteur Financier, Luxembourg.
- in Dubai by Invesco Asset Management Limited, Index Tower Level 6 Unit 616, P.O. Box 506599, Al Mustaqbal Street, DIFC, Dubai, United Arab Emirates. Regulated by the Dubai Financial Services Authority.
- in the Isle of Man, Jersey, Guernsey and the UK by Invesco Asset Management Limited, Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire, RG91HH, United Kingdom. Authorised and regulated by the Financial Conduct Authority.
- in Switzerland by Invesco Asset Management (Schweiz) AG, Talacker 34, 8001 Zurich, Switzerland.